marijuana stock news

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Fourth Quarter and Year Ending December 31, 2019 and Host Conference Call on February 25th, 2020

 

Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on February 25th, 2020 its financial results for the fourth quarter and year ending December 31st, 2019. GW will also host a conference call the same day at 4:30 p.m. ET. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company’s website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution, CV, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. This product has received approval in the European Union under the tradename EPIDYOLEX®. The Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication for Epidiolex to include seizures associated with Tuberous Sclerosis Complex (TSC), for which it has reported positive Phase 3 data, and is carrying out a Phase 3 trial in Rett syndrome. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as for the treatment of PTSD. The Company has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$RSSFF Announces 2 Year Contract with Cannabis Laboratory

Affinor Growers: Herbal Analytics Signs 2-Year Contract with Medical Producer as Cannabis…

Neptune Wellness Solutions Inc. (NEPT) Reports Fourth Quarter and Fiscal 2020 Results

Neptune Reports Fourth Quarter and Fiscal 2020 Results Neptune Wellness Solutions Inc.…

$AFI Closes 700,000 Units Private Placement

Affinor Growers Closes 700,000 Units Private Placement MONTREAL, CANADA–(Marketwired – Feb 11,…

Reliq Health Technologies Inc. (RQHTF) Announces Call-In Details for Quarterly Reporting Call to Take Place on May 31, 2018

Reliq Health Announces Call-In Details for Quarterly Reporting Call to Take Place…